Prognostic values of immune efficacy biomarkers in the treatment of nasopharyngeal carcinoma
10.3760/cma.j.cn371439-20201120-00147
- VernacularTitle:免疫疗效生物标志物在鼻咽癌治疗中的预测价值
- Author:
Wenxiao LUO
1
;
Dehua WU
;
Longmei CAI
Author Information
1. 南方医科大学南方医院放疗科，广州 510515
- Keywords:
Nasopharyngeal neoplasms;
Immunotherapy;
Biomarkers, tumor
- From:
Journal of International Oncology
2021;48(12):743-746
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy has achieved objective response rates of 20%-30% in patients with recurrent or metastatic nasopharyngeal carcinoma, but fewer people are benefiting. Studies have shown that patients with nasopharyngeal carcinoma carrying high expression of programmed death-1/programmed death-ligand 1 and/or high tumor mutation burden have a significant response to immunotherapy. Biomarkers of the tumor microenvironment, especially tumor infiltrating lymphocyte, are abundant in nasopharyngeal carcinoma, varying from different Epstein-Barr virus states, which can also play a predictive role of immunotherapy efficacy. Other biomarkers, such as mismatch repair-deficient, have a low incidence in nasopharyngeal carcinoma and limited predictive power. Combined detection of different types of immunotherapeutic biomarkers is more helpful to identify suitable populations for immunotherapy.
